Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cellectricon AB
Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.
Automated medium- and high-throughput ion channel screening systems promise to jump start the search for ion channel modulating drugs, a vast and promising area of drug discovery. In Vivo Europe Rx looks at Sophion Bioscience, Nanion Technologies, and Xention Discovery, three emerging European firms whose platforms may help return ion channels to the forefront of biotech and pharmaceutical companies' discovery targets.
- Research, Analytical Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.